Asthma Clinical Trial
— PIANOFORTEOfficial title:
Optimal Self-Management Of Asthma By Forced Oscillation Technique: a Randomised Controlled Trial
NCT number | NCT04963140 |
Other study ID # | 1/20 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | November 16, 2020 |
Est. completion date | September 2024 |
Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma outcomes and possibly reduce the risk of future exacerbations. However, the real-life evidence is that asthma control remains sub-optimal in the majority of cases, thus increasing the related socio-economic costs worldwide. Because an increased variability of lung function remains a hallmark of poor asthma control and exacerbations, its assessment over time could contribute to the success of self-management plans. Previous studies have shown the potential of Forced Oscillation Technique (FOT) as a tool for monitoring increased variability of airway obstruction and for identifying the onset of acute deterioration of airway function. The aim of this study is to test the hypothesis that a personalised self-management plan including FOT improves asthma control and reduces number of days with increased symptoms compared to conventional asthma treatment.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | September 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age: 6-65 years old - Diagnosis of persistent asthma - Treatment level at study entry: - For children 6-11 years: Step2 or Step3 of the GINA document - For adolescents and adults 12-65 years: Step2 under daily low-dose inhaled corticosteroids (ICS), Step 3 or Step 4 of the GINA document - Uncontrolled asthma (ACQ-5 > 1.5) that, according to the physician, does not warrant an immediate step-up of the treatment - History of moderate or severe exacerbations in the twelve (12) months prior to baseline visit Exclusion Criteria: - Use of oral, rectal or parenteral glucocorticosteroids 30 days before enrolment - Treatment with leukotriene receptor antagonist (LTRA) - Treatment with maintenance and reliever therapy (SMART/MART) - Smoking, current or previous with a history of 10 pack-years or more - Documented COPD or other concomitant clinically important diseases or cognitive impairment that, according to the physician, may interfere with the subject's ability or safety to participate in the study - Obesity (for subjects 6-19 years: BMI = 95th percentile; for adults 20-65 years: BMI = 40kg·m-2 - For school-age children (6-11 years old): gestational age at birth < 37 weeks or documented bronchopulmonary dysplasia (BPD) - Prolonged absence from home during the monitoring period (i.e. at recruitment, expected =3 consecutive weeks for =2 times during the 9- month monitoring period) Subject currently enrolled in other clinical trials related or involving the study of the respiratory system - History of near-fatal asthma - Women who are pregnant, nursing or intending to become pregnant during the time of the study - Absence of health insurance coverage (applies to French centres only) |
Country | Name | City | State |
---|---|---|---|
Australia | Woolcock Institute of Medical Research | Sydney | |
France | Grenoble University Hospital | Grenoble | |
France | University Children's Hospital of Nancy | Nancy | |
Italy | AOU Ospedali Riuniti Ancona | Ancona | |
Italy | ASST Papa Giovanni XXIII | Bergamo | |
Italy | Azienda Ospedaliero, Universitaria Meyer | Firenze | FI |
Italy | Istituto di Farmacologia Traslazionale (IFT) del CNR | Palermo | |
Italy | Istituto di Farmacologia Traslazionale (IFT) del CNR | Palermo | |
Italy | Fondazione IRCCS Policlinico S. Matteo | Pavia | |
Italy | Azienda Unità Sanitaria Locale di Reggio Emilia | Reggio Emilia |
Lead Sponsor | Collaborator |
---|---|
Restech Srl |
Australia, France, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) | 6 months from enrolment | |
Primary | Symptoms | Change of percentage of days with non-increased symptoms from baseline | From month no. 2 through study completion, an average of 7 months | |
Secondary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) | 3 months from enrolment | |
Secondary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) | 9 months from enrolment | |
Secondary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) moving from uncontrolled to controlled asthma | 3 months from enrolment | |
Secondary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) moving from uncontrolled to controlled asthma | 6 months from enrolment | |
Secondary | Asthma Control | Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5) moving from uncontrolled to controlled asthma | 9 months from enrolment | |
Secondary | Asthma Control | Change of percentage of adolescent and adult subjects (12+ years old) who improve their Asthma Control Questionnaire (ACQ-5) | 3 months from enrolment | |
Secondary | Asthma Control | Change of percentage of adolescent and adult subjects (12+ years old) who improve their Asthma Control Questionnaire (ACQ-5) | 6 months from enrolment | |
Secondary | Asthma Control | Change of percentage of adolescent and adult subjects (12+ years old) who improve their Asthma Control Questionnaire (ACQ-5) | 9 months from enrolment | |
Secondary | Asthma Control | Change of mean Asthma Control Questionnaire (ACQ-5); the expected ACQ-5 range is 0 - 3.5, with lower values indicating better asthma outcome | 3 months from enrolment | |
Secondary | Asthma Control | Change of mean Asthma Control Questionnaire (ACQ-5); the expected ACQ-5 range is 0 - 3.5, with lower values indicating better asthma outcome | 6 months from enrolment | |
Secondary | Asthma Control | Change of mean Asthma Control Questionnaire (ACQ-5); the expected ACQ-5 range is 0 - 3.5, with lower values indicating better asthma outcome | 9 months from enrolment | |
Secondary | Exacerbation | Change of number of moderate and severe exacerbations | Through study completion, an average of 9 months | |
Secondary | Controller medication usage | Change of days with increased controller (inhaled corticosteroid (ICS) alone or in combination with long-acting bronchodilator (LABA)) | From month no. 2 through study completion, an average of 7 months | |
Secondary | Absence days from school/work | Change of absence days from work/school due to asthma | Through study completion, an average of 9 months | |
Secondary | Day-to-day variability of respiratory resistance | Change of average day-to-day coefficient of variation of inspiratory resistance (CVRinsp) | Through study completion, an average of 9 months | |
Secondary | Accuracy of CVRinsp in detecting exacerbations | In the control arm of the study only: accuracy, sensitivity and specificity of day-to-day variability of FOT parameters and of related prediction algorithm in identifying the occurrence of future moderate and severe exacerbations | Through study completion, an average of 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|